收藏切换
Introduction to the patient medication information for prescription drugs in the US
收藏切换
PDF
Fan ZHANG, Meng-die ZHOU, Zhen-yu XU
Chinese Journal of Clinical Pharmacology | 2025, 41(24) : 3580 - 3587
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(24): 3580-3587
Drug Evaluation and Administration
Introduction to the patient medication information for prescription drugs in the US
Full
Fan ZHANG, Meng-die ZHOU, Zhen-yu XU
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
Published: 2025-12-28 doi: 10.13699/j.cnki.1001-6821.2025.24.021
Outline
收藏切换

To give patients a more scientific instruction of prescription drugs, drug regulatory authorities in developed countries such as Europe, the United States, and Japan are actively promoting the establishment of patient labeling system. Unlike professional labeling, patient labeling uses easy-to-understand language to help patients understand the most critical information about the drug, thereby enabling safer use of prescription drugs. This article focuses on the U.S. Food and Drug Administration(FDA)′s patient labeling system, briefly introducing the main content and relevant requirements of different types of patient labeling, such as the medication guides (MG), patient package inserts (PPI), instructions for use (IFU), and consumer medication information (CMI). It also provides a detailed introduction to the scope of application, specific content, and format requirements of the patient medication information (PMI) that the FDA is currently promoting, while giving a brief explanation of the patient labeling systems of other drug regulatory authorities (such as the European Union and Japan). PMI is a new form of patient labeling further optimized by the FDA based on previous experience in patient labeling work, and it plans to gradually unify and replace the original MG and PPI. In China, the State Council issued and implemented the Law of the People′s Republic of China on the Construction of Accessible Environments in 2023, requiring drug manufacturers and operators to provide labels and instructions in accessible formats such as audio, large print, braille, and electronic versions. In the same year, the National Medical Products Administration (NMPA) issued a public notice to promote the pilot work on aging-friendly labeling. By sorting out and summarizing the practical experience of the FDA′s patient labeling system and comparing it with the current pilot work on aging-friendly labeling in China, this article provides insights and references for promoting the establishment of a patient labeling system in China.

U.S. Food and Drug Administration  /  patient labeling  /  patient medication information  /  policy
Fan ZHANG, Meng-die ZHOU, Zhen-yu XU. Introduction to the patient medication information for prescription drugs in the US[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (24) : 3580 -3587 . DOI: 10.13699/j.cnki.1001-6821.2025.24.021
Year 2025 volume 41 Issue 24
PDF
176
38
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.24.021
  • Receive Date:2025-08-21
  • Online Date:2026-08-05
  • Published:2025-12-28
Article Data
Affiliations
History
  • Received:2025-08-21
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.24.021
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT